Transactions

Our broad-based transaction experience extends across a range of situations, industries and enterprise values

Type

Industry

Paramount Skydance Corporation

Announced: February 26, 2026
Value: $110 billion
Status: Pending

Lead financial advisor to Paramount on its acquisition of Warner Bros. Discovery

Banco Santander S.A.

Announced: February 3, 2026
Value: $12.2 billion
Status: Pending

Exclusive financial advisor to Santander on its acquisition of Webster Financial Corporation

FedEx Corporation

Announced: February 9, 2026
Value: $12 billion
Status: Pending

Exclusive advisor to FedEx on its partnership with Advent International to make an investment for joint ownership of InPost

Masimo Corporation

Announced: February 17, 2026
Value: $9.9 billion
Status: Pending

Financial advisor to Masimo Corporation on its sale to Danaher

Arcellx

Announced: February 23, 2026
Value: Up to $8.2 billion
Status: Pending

Exclusive financial advisor to Arcellx on its sale to Gilead Sciences

Centessa Pharmaceuticals

Announced: March 31, 2026
Value: Up to $7.8 billion
Status: Pending

Lead financial advisor to Centessa Pharmaceuticals on its acquisition by Eli Lilly

Terns Pharmaceuticals, Inc.

Announced: March 25, 2026
Value: $6.7 billion
Status: Pending

Lead financial advisor to Terns Pharmaceuticals on its sale to Merck

OneStream

Announced: January 6, 2026
Value: $6.4 billion
Status: Pending

Financial advisor to OneStream on its acquisition by Hg

Brex

Announced: January 22, 2026
Value: $5.15 billion
Status: Pending

Exclusive financial advisor to Brex on its sale to Capital One

Mister Car Wash

Announced: February 18, 2026
Value: $3.1 billion
Status: Pending

Financial advisor to the special committee for Mister Car Wash

Synnovation Therapeutics

Announced: March 20, 2026
Value: Up to $3 billion
Status: Pending

Exclusive financial advisor to Synnovation on its sale of Pikavation to Novartis

Day One Biopharmaceuticals

Announced: March 6, 2026
Value: $2.5 billion
Status: Pending

Exclusive financial advisor to Day One on its sale to Servier

The Clorox Company

Announced: January 22, 2026
Value: $2.25 billion
Status: Pending

Exclusive financial advisor to Clorox on its acquisition of GOJO Industries

Jacobs Solutions

Announced: January 5, 2026
Value: $1.6 billion
Status: Pending

Financial advisor to Jacobs on its acquisition of the remaining shares of PA Consulting

Honeywell

Announced: April 20, 2026
Value: $1.4 billion
Status: Pending

Exclusive financial advisor to Honeywell on the sale of its Productivity Solutions and Services business to Brady Corporation

Deutsche Börse AG

Announced: February 12, 2026
Value: $1.3 billion
Status: Pending

Exclusive financial advisor to Deutsche Börse on its acquisition of the remaining stake in ISS STOXX

SEEQC, Inc.

Announced: January 16, 2026
Value: $1 billion
Status: Pending

Financial advisor to SEEQC on its agreement to combine with Allegro Merger Corp, supported by a $65 million PIPE financing

35Pharma

Announced: February 25, 2026
Value: $950 million
Status: Pending

Lead financial advisor to 35Pharma on its sale to GSK

Corium LLC

Announced: March 19, 2026
Value: Up to $785 million
Status: Pending

Exclusive financial advisor to Corium on its sale of AZSTARYS to Collegium Pharmaceutical

D-Wave

Announced: January 7, 2026
Value: $550 million
Status: Pending

Exclusive financial advisor to D-Wave on its acquisition of Quantum Circuits

Bachan’s, Inc.

Announced: February 4, 2026
Value: $400 million
Status: Pending

Exclusive financial advisor to Bachan's on its sale to The Marzetti Company

Surf Bio

Announced: January 28, 2026
Value: Up to $400 million
Status: Pending

Exclusive financial advisor to Surf Bio on its sale to Halozyme Therapeutics

HCSS Construction Software

Announced: April 13, 2026
Status: Pending

Financial advisor to Thoma Bravo and HCSS on HCSS’ combination with Nemetschek Group’s Build & Construct segment

iBase-T

Announced: March 29, 2026
Status: Closed

Financial advisor to iBase-t on its strategic growth investment from TA Associates

Transcend Therapeutics

Announced: March 27, 2026
Value: Up to $1.225bn
Status: Pending

Exclusive financial advisor to Transcend on its sale to Otsuka

Gilead

Announced: March 23, 2026
Value: Up to $2.175bn
Status: Pending

Exclusive financial advisor to Gilead on its acquisition of Ouro Medicines

Huel

Announced: March 23, 2026
Status: Pending

Exclusive financial advisor to Huel on its sale to Danone

1touch

Announced: February 23, 2026
Status: Pending

Exclusive financial advisor to 1touch on its sale to Everpure

Linden Capital Partners

Announced: February 9, 2026
Status: Pending

Lead financial advisor to Linden on their agreement to sell a 50% stake in Regenity Biosciences to Cinven

Radius Health

Announced: January 12, 2026
Status: Pending

Financial advisor to Radius on B FLEXION's acquisition of the remaining interest in Radius

Blackstone

Announced: January 7, 2026
Status: Closed

Lead financial advisor to Blackstone on its acquisition of the remaining stake in AIR Control Concepts

Showing 1 to 31 of 31
Centerview Partners takes a “One Firm” approach to deliver unmatched intellectual capital and integrity to all of our clients. We have industry-leading expertise in:

At Centerview Partners, our success depends on our people, and we are always looking for talented individuals. Please let us know if you would like to learn more about a career at Centerview.
Our Partners have worked on many of the largest and most complex transactions and corporate situations around the globe over the course of their careers. Learn more about who we are.
New York

Centerview Partners LLC


31 West 52nd Street

22nd Floor

New York, New York 10019

(212) 380-2650 | Tel
(212) 380-2651 | Fax
London

Centerview Partners UK LLP


1 Sherwood Street

6th Floor

London W1F 7BL

02074099700 | Tel
02074099704 | Fax
Paris

Centerview Partners France SCS


51 Avenue Hoche


Paris 75008

0180200620 | Tel
0180200621 | Fax
Menlo Park

Centerview Partners LLC


1302 El Camino Real

Suite 350

Menlo Park, California 94025

(650) 822-5800 | Tel
(650) 822-5801 | Fax
San Francisco

Centerview Partners LLC


555 California Street

Suite 4300

San Francisco, California 94104

(415) 400-0900 | Tel
(415) 400-0901 | Fax





Copyright © 2008 - 2026 Centerview Partners Holdings LP. All Rights Reserved. | Privacy and Other Notices

Centerview Partners LLC, member SIPC